矛盾反应与生物制剂:一项9303例法国队列研究
这项多中心研究基于大巴黎大学医院数据库,纳入9303例接受抗TNF-α、抗IL-12/23、抗IL-17或抗α4β7整合素治疗的生物制剂初治患者。297例(3.2%)发生矛盾反应,总发生率为7.6/1000人年(95%CI 6.8-8.5)。矛盾反应与炎症性肠病及至少两种炎症性疾病组合相关,而联用传统合成改善病情抗风湿药或糖皮质激素可降低风险。
要点
- 9303例生物制剂初治患者中297例(3.2%)发生矛盾反应,总发生率7.6/1000人年。
- 炎症性肠病(aOR 1.9)及至少两种炎症性疾病组合(aOR 6.1)与矛盾反应风险升高相关。
- 联用传统合成改善病情抗风湿药(aOR 0.6)或糖皮质激素(OR 0.4)与矛盾反应风险降低相关。
核心结论
- 矛盾反应的发生风险与炎症性肠病或至少两种炎症性疾病组合相关。
- 需要更多研究评估对这类高危患者系统性加用传统合成改善病情抗风湿药的获益。
研究设计与样本
- 多中心研究,基于大巴黎大学医院数据库,纳入接受抗TNF-α、抗IL-12/23、抗IL-17或抗α4β7整合素治疗的生物制剂初治患者,共9303例。
- 使用自然语言处理算法提取数据,采用队列研究及巢式病例对照研究(对照通过发病密度抽样选取)识别危险因素。
主要发现
- 9303例患者中位年龄43.0岁,女性占53.8%;炎症性肠病3773例(40.6%),慢性炎症性风湿病3708例(39.9%),8489例(91.3%)接受抗TNF-α治疗。
- 297例(3.2%)发生矛盾反应,总发生率为7.6/1000人年(95%CI 6.8-8.5)。
- 矛盾反应与炎症性肠病相关(aOR 1.9,95%CI 1.1-3.2,P=0.021),与至少两种炎症性疾病组合相关(aOR 6.1,95%CI 3.6-10.6,P<0.001)。
- 联用传统合成改善病情抗风湿药(aOR 0.6,95%CI 0.4-0.8,P=0.002)或糖皮质激素(OR 0.4,95%CI 0.2-0.6,P=0.002)与矛盾反应风险降低相关。
临床怎么用
- 作者认为,对于炎症性肠病或至少两种炎症性疾病组合等高危患者,可考虑加用传统合成改善病情抗风湿药,但需更多研究评估其获益。
局限性
- 需要更多研究评估对高危患者系统性加用传统合成改善病情抗风湿药的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paradoxical reactions (PRs) are defined as the occurrence during biologic therapy of a pathological condition that usually responds to these drugs. OBJECTIVES: To estimate the incidence of PRs and identify risk factors. METHODS: Multicentre study of the database for the Greater Paris University Hospitals, including biologic-naive patients receiving anti-tumour necrosis factor-α, anti-interleukin-12/23, anti-interleukin-17 or anti-α4β7-integrin agents for psoriasis, inflammatory rheumatism or inflammatory bowel disease (IBD). We used natural language processing algorithms to extract data. A cohort and a case-control study nested in the cohort with controls selected by incidence density sampling was used to identify risk factors. RESULTS: Most of the 9303 included patients (median age 43·0, 53·8% women) presented an IBD (3773, 40·6%) or a chronic inflammatory rheumatic disease (3708, 39·9%), and 8489 (91·3%) received anti-TNF-α agents. A total of 297 (3·2%) had a PR. The global incidence rate was 7·6 per 1000 person-years [95% confidence interval (CI) 6·8-8·5]. The likelihood of PR was associated with IBD [adjusted odds ratio (aOR) 1·9, 95% CI 1·1-3·2, P = 0·021] and a combination of at least two inflammatory diseases (aOR 6·1, 95% CI 3·6-10·6, P < 0·001) and was reduced with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and corticosteroids (aOR 0·6, 95% CI 0·4-0·8, P = 0·002; and OR 0·4, 95% CI 0·2-0·6, P = 0·002, respectively). CONCLUSIONS: The likelihood of PRs was associated with IBD or a combination of a least two inflammatory diseases. More studies are needed to assess the benefit of systematically adding csDMARDs for such high-risk patients. What is already known about this topic? Most published studies about paradoxical reactions concern paradoxical psoriasis in patients receiving anti-tumour necrosis factor-α agents. Few data are available for other paradoxical reactions and the most recent biologics. What does this study add? Risk of paradoxical reactions was increased with inflammatory bowel disease and a combination of at least two inflammatory diseases. Risk of paradoxical reactions was reduced with conventional synthetic disease-modifying antirheumatic drugs or corticosteroid therapy, which could be added for high-risk patients.
引用
- Bataille P, Layese R, Claudepierre P, et al. Paradoxical reactions and biologic agents: a French cohort study of 9303 patients. Br J Dermatol. 2022. PMID: 35770735. doi:10.1111/bjd.21716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。